Joan E. Smallshaw

907 total citations
21 papers, 689 citations indexed

About

Joan E. Smallshaw is a scholar working on Immunology, Biotechnology and Molecular Biology. According to data from OpenAlex, Joan E. Smallshaw has authored 21 papers receiving a total of 689 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Immunology, 11 papers in Biotechnology and 9 papers in Molecular Biology. Recurrent topics in Joan E. Smallshaw's work include Toxin Mechanisms and Immunotoxins (11 papers), Transgenic Plants and Applications (11 papers) and Monoclonal and Polyclonal Antibodies Research (9 papers). Joan E. Smallshaw is often cited by papers focused on Toxin Mechanisms and Immunotoxins (11 papers), Transgenic Plants and Applications (11 papers) and Monoclonal and Polyclonal Antibodies Research (9 papers). Joan E. Smallshaw collaborates with scholars based in United States, Canada and Czechia. Joan E. Smallshaw's co-authors include Ellen S. Vitetta, James A. Richardson, John Schindler, Victor Gheţie, Seth H. Pincus, Maria‐Ana Ghetie, Hasan S. Jafri, Laurentiu M. Pop, Robert S. Munford and D. Gomika Udugamasooriya and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Biotechnology and The Journal of Immunology.

In The Last Decade

Joan E. Smallshaw

21 papers receiving 665 citations

Peers

Countries citing papers authored by Joan E. Smallshaw

Since Specialization

Citations

This map shows the geographic impact of Joan E. Smallshaw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joan E. Smallshaw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joan E. Smallshaw more than expected).

Fields of papers citing papers by Joan E. Smallshaw

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joan E. Smallshaw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joan E. Smallshaw. The network helps show where Joan E. Smallshaw may publish in the future.

Co-authorship network of co-authors of Joan E. Smallshaw

This figure shows the co-authorship network connecting the top 25 collaborators of Joan E. Smallshaw. A scholar is included among the top collaborators of Joan E. Smallshaw based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joan E. Smallshaw. Joan E. Smallshaw is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The development of a novel anti-peptoid antibody for a peptoid-based vaccine platform (P4506) 2013 ·The Journal of Immunology ·(unknown), (unknown), (unknown), Joan E. Smallshaw, Angela C. Collins, (unknown), (unknown), (unknown), John Chen, Helen Tran, Michael D. Connolly, Ronald N. Zuckermann, Sara Chirayil, Kevin J Luebke, John Astle, M. Vijayaraj Reddy, Thomas Kodadek, Ellen S. Vitetta	2
2	Pilot Phase IB Clinical Trial of an Alhydrogel-Adsorbed Recombinant Ricin Vaccine 2012 ·Clinical and Vaccine Immunology ·Ellen S. Vitetta, Joan E. Smallshaw, John Schindler	43
3	Ricin Vaccine Development 2011 ·Current topics in microbiology and immunology ·Joan E. Smallshaw, Ellen S. Vitetta	32
4	Structure of RiVax: a recombinant ricin vaccine 2011 ·Acta Crystallographica Section D Biological Crystallography ·Patricia M. Legler, Robert N. Brey, Joan E. Smallshaw, Ellen S. Vitetta, Charles B. Millard	27
5	Intradermal administration of RiVax protects mice from mucosal and systemic ricin intoxication 2010 ·Vaccine ·(unknown), Joan E. Smallshaw, Laurentiu M. Pop, (unknown), Ellen S. Vitetta	25
6	A lyophilized formulation of RiVax, a recombinant ricin subunit vaccine, retains immunogenicity 2010 ·Vaccine ·Joan E. Smallshaw, Ellen S. Vitetta	23
7	A VEGFR2 Antagonist and Other Peptoids Evade Immune Recognition 2008 ·International Journal of Peptide Research and Therapeutics ·John Astle, D. Gomika Udugamasooriya, Joan E. Smallshaw, Thomas Kodadek	37
8	RiVax, a recombinant ricin subunit vaccine, protects mice against ricin delivered by gavage or aerosol 2007 ·Vaccine ·Joan E. Smallshaw, James A. Richardson, Ellen S. Vitetta	77
9	The Fc Portion of UV3, an Anti-CD54 Monoclonal Antibody, Is Critical for its Antitumor Activity in SCID Mice With Human Multiple Myeloma or Lymphoma Cell Lines 2006 ·Journal of Immunotherapy ·(unknown), (unknown), Joan E. Smallshaw, Ellen S. Vitetta	13
10	A pilot clinical trial of a recombinant ricin vaccine in normal humans 2006 ·Proceedings of the National Academy of Sciences ·Ellen S. Vitetta, Joan E. Smallshaw, (unknown), Hasan S. Jafri, (unknown), Robert S. Munford, John Schindler	71
11	Failure of Vaccination With Idiotypic Protein or DNA, (+/???IL-2), the Depletion of Regulatory T Cells, or the Blockade of CTLA-4 to Prolong Dormancy in Mice With BCL1 Lymphoma 2005 ·Journal of Immunotherapy ·Laurentiu M. Pop, Joan E. Smallshaw, Thomas F. Tucker, Freda K. Stevenson, Ellen S. Vitetta	4
12	Generation and characterization of a novel tetravalent anti-CD22 antibody with improved antitumor activity and pharmacokinetics 2005 ·International Immunopharmacology ·Xiaoyun Liu, Laurentiu M. Pop, Derry C. Roopenian, Victor Gheţie, Ellen S. Vitetta, Joan E. Smallshaw	11
13	Preclinical toxicity and efficacy testing of RiVax, a recombinant protein vaccine against ricin 2005 ·Vaccine ·Joan E. Smallshaw, James A. Richardson, Seth H. Pincus, John Schindler, Ellen S. Vitetta	60
14	The Generation and Anti-Myeloma Activity of a Chimeric Anti-CD54 Antibody, cUV3 2004 ·Journal of Immunotherapy ·Joan E. Smallshaw, (unknown), (unknown), Ellen S. Vitetta	7
15	The Evaluation of Recombinant, Chimeric, Tetravalent Antihuman CD22 Antibodies 2004 ·Clinical Cancer Research ·(unknown), Joan E. Smallshaw, Laurentiu M. Pop, (unknown), Xiaoyun Liu, (unknown), Maria-Ana Ghetie, Ellen S. Vitetta, Victor Gheţie	18
16	Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice 2003 ·Nature Biotechnology ·Joan E. Smallshaw, Victor Gheţie, (unknown), (unknown), (unknown), Maria‐Ana Ghetie, Ellen S. Vitetta	107
17	A novel recombinant vaccine which protects mice against ricin intoxication 2002 ·Vaccine ·Joan E. Smallshaw	77
18	Synthesis, cloning and expression of the single-chain Fv gene of the HPr-specific monoclonal antibody, Jel42. Determination of binding constants with wild-type and mutant HPrs 1999 ·Protein Engineering Design and Selection ·Joan E. Smallshaw, (unknown), Jeremy S. Lee, E. Bruce Waygood	13
19	Determination of the binding constants for three HPr-specific monoclonal antibodies and their Fab fragments 1998 ·Journal of Molecular Biology ·Joan E. Smallshaw, S. Brokx, Jeremy S. Lee, E. Bruce Waygood	11
20	Construction and characterization of the HPr-specific Jel42 scFv antibody fragment 1997 ·University Library - University of Saskatchewan (University of Saskatchewan) ·Joan E. Smallshaw	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact